Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Shares of Moderna, Inc. ($MRNA), among the frontrunners in mRNA vaccine technology, fell on Tuesday, bucking the broader market strength. The weakness came after Bloomberg reported, citing a person ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other most promising gene ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $59 from $70 and keeps an Underweight rating on the shares. The firm updated estimates following Pfizer’s Comirnaty ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Moderna, a biotech giant that gained prominence during the COVID-19 pandemic, has revolutionized the biotechnology domain.

By Mark Gargarian Noubar and Anna Afeyan first met in 1986 at an American Chemical Society meeting in Anaheim, California.

Vermont has the second lowest state fatality rate in the US (141.1 per 100K; Hawaii 111.7/100K). Mississippi (457.4/100K) and ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 ...